Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:6:33-9.
doi: 10.2147/OPTH.S15028. Epub 2011 Dec 30.

Improving quality of life in patients with end-stage age-related macular degeneration: focus on miniature ocular implants

Michael A Singer  1 , Nancy Amir, Angela Herro, Salman S Porbandarwalla, Joseph Pollard
Affiliations

Improving quality of life in patients with end-stage age-related macular degeneration: focus on miniature ocular implants

Michael A Singer et al. Clin Ophthalmol. 2012.

Abstract

Low vision devices in the past have been mainly extraocular. There are now four new devices in different stages of development and implementation that are currently available. Three of them, the Implantable Miniature Telescope (IMT, VisionCare Ophthalmic Technologies, Saratoga, CA), Intraocular Lens for Visually Impaired People (IOL-VIP, IOL-VIP System, Soleko, Pontecorvo, Italy), and Lipschitz Mirror Implant (LMI, Optolight Vision Technology, Herzlia, Israel) are implanted into the anterior segment while the Argus II (Second Sight Medical Products, Sylmar, CA) is implanted into the posterior segment. The goal of these devices is to increase the patient quality of life which has been measured by Visual Functioning Questionnaire (VFQ) scales. The IMT is the only device that has been shown to increase the VFQ score by seven points at 6 months compared to baseline. It is the only FDA-approved device in the US while the Argus has been approved in Europe. Each of these prosthetics has potential benefits for patients.

Keywords: Argus II; IMT; IOL-VIP; LMI.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Implantable Miniature Telescope (IMT by Dr Isaaz Lipshitz; VisionCare Ophthalmic Technologies, Saratoga, CA, USA).
Figure 2
Figure 2
Intraocular Lens for Visually Impaired People (IOL-VIP System; Soleko, Pontecorvo, Italy).
Figure 3
Figure 3
Lipshitz Mirror implant (LMI; Optolight Vision Technology, Herzlia, Israel).
Figure 4
Figure 4
Argus II (Second Sight Medical Products, Sylmar, CA, USA).
See this image and copyright information in PMC

References

    1. Friedman DS, O’Colmain BJ, Munoz B, et al. for the Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564–572. - PubMed
    1. Gohdes DM, Balamurugan A, Larsen BA, Maylahn C. Age related eye diseases: an emerging challenge for public health professionals. [Accessed August 1, 2011];Prev Chronic Dis. 2005 2(3):A17. Available from: http://www.cdc.gov/pcd/issues/2005/jul/04_0121.htm. - PMC - PubMed
    1. AREDS Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, β-carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 9. Arch Ophthalmol. 2001;119(10):1439–1452. - PMC - PubMed
    1. Chun DW, Heier JS, Raizman MB. Visual Prosthetic Device for bilateral end-stage macular degeneration. Expert Rev Med Devices. 2005;2(6):657–665. - PubMed
    1. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37(5):855–868. - PubMed